Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 3

of 'Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-resistant disease'

Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial.
Seewaldt VL, Greer BE, Cain JM, Figge DC, Tamimi HK, Brown WS, Miller SA
Am J Obstet Gynecol. 1994;170(6):1666.
OBJECTIVE: Our aim was to determine the efficacy and toxicity of paclitaxel in the treatment of refractory and platinum-resistant epithelial ovarian cancer.
STUDY DESIGN: Eligibility required three prior failed chemotherapy regimens and documented platinum resistance. One hundred patients with advanced ovarian cancer received paclitaxel 135 mg/m2 over 24 hours every 21 days with optional granulocyte colony-stimulating factor support.
RESULTS: Paclitaxel was generally well tolerated. In four patients bowel perforation or fistula developed. After three cycles 34% of patients had stable disease and 25% of patients demonstrated a response, either partial or complete. After six cycles 24% of patients continued to respond. To date, six patients have achieved a complete response.
CONCLUSION: A 25% response rate in patients with refractory ovarian cancer was observed, which was durable to six cycles.
Department of Medicine, University of Washington Medical Center 98155.